NDAORALTABLET2 Generics Approved
Approved
Nov 1982
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Data completeness
2/8 — Basic
Drug data last refreshed 2d ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDIZEM (diltiazem hydrochloride) is a non-dihydropyridine calcium channel blocker approved in 1982 for cardiovascular indications including angina and hypertension. It works by inhibiting calcium influx into vascular smooth muscle and cardiac tissue, reducing contractility and heart rate. The drug is administered orally in tablet form.
LOE Approaching
With LOE approaching and 60% competitive pressure, the brand team likely focuses on managed care defense and generic transition planning rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CARDIZEM offers limited growth but provides deep expertise in managed care, generic transition, and portfolio defense—valuable skills for LOE management roles. Roles are primarily defensive rather than growth-oriented, making this suitable for professionals interested in operational excellence and cost-containment strategy.
Brand ManagerField Sales Representative
Worked on CARDIZEM at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.